Two key things in this preso and forget the rest:
1. tie-up with global medical device distributors at the 'decision maker' stage.
2. re-domiciling to the US by 2017.
Make or break - if this comes off, this will re-rate hard. If not, then you are relying on funding a global marketing strategy using deeply discounted cap raisings. Otherwise known as a road to nowhere fast!